Cancer clinical trials in the region Occitanie

174 currently recruiting clinical trials
Region Occitanie

Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR Targeted therapy
Systemic Treatment-Naive
6 main criterias to confirm
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR Systemic Treatment-Naive None
6 main criterias to confirm
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced EGFR Chemotherapy Radiotherapy None
7 main criterias to confirm
AstraZeneca
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Localized ALK Systemic Treatment-Naive Surgery None
6 main criterias to confirm
Hoffmann-La Roche
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Localized Systemic Treatment-Naive PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None
ALK EGFR
7 main criterias to confirm
Bristol-Myers Squibb
Early Access Lung cancer
SCLC (Small Cell Lung Cancer) Localized Locally Advanced Chemotherapy Radiotherapy Chemotherapy Radiotherapy None
6 main criterias to confirm
AstraZeneca
Phase 3 Lung cancer
#NCT06417814
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic EGFR Targeted therapy
Chemotherapy Systemic Treatment-Naive Immunotherapy Chemotherapy
8 main criterias to confirm
Centre de Cancérologie du Grand Montpellier (Montpellier)
AstraZeneca
Phase 3 Lung cancer
#NCT06472245
NSCLC (Non-Small Cell Lung Cancer) Metastatic Other mutation Immunotherapy
ALK EGFR ROS-1
6 main criterias to confirm
Hôpital Larrey (Toulouse )
OSE Immunotherapeutics
Phase 3 Breast cancer
#NCT06195709
HER2 Negative HR Positive Metastatic Targeted therapy Hormone therapy 1
Chemotherapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
7 main criterias to confirm
Institut du cancer de Montpellier (Montpellier)
Institut Curie
Phase 3 Prostate cancer
#NCT06136624
Adenocarcinoma Metastatic Castration-resistant Chemotherapy Hormone therapy 1 2 3 or more
Systemic Treatment-Naive
6 main criterias to confirm
Institut de cancérologie du Gard (Nîmes)
Merck Sharp & Dohme LLC